(28 days)
Not Found
No
The device description details a standard clinical chemistry assay based on enzymatic reactions and spectrophotometry, with no mention of AI or ML. The performance studies focus on traditional analytical metrics like correlation, precision, linearity, and sensitivity. There is no mention of training or test sets, which are typical for AI/ML models.
No.
This device is an in vitro diagnostic assay used for the quantitative determination of urea nitrogen, which aids in diagnosis and treatment but does not directly provide therapy.
Yes
The "Intended Use / Indications for Use" section explicitly states that "Measurements obtained by this device are used in diagnosis and treatment of certain renal and metabolic diseases."
No
The device description clearly states it is an "in vitro diagnostic assay" and describes a chemical reaction process involving reagents and measurement of absorbance, which are hardware-dependent processes. It also mentions comparative studies using specific analyzers (ALCYON™, Roche Cobas Mira Plus, Hitachi 717), indicating reliance on physical laboratory equipment.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The "Intended Use / Indications for Use" section explicitly states that the assay is used for the quantitation of urea nitrogen in human serum, plasma, or urine and that the measurements are used in the diagnosis and treatment of certain renal and metabolic diseases. This directly aligns with the definition of an IVD, which is a medical device intended for use in vitro for the examination of specimens derived from the human body solely or principally for the purpose of providing information concerning a physiological or pathological state, or a congenital abnormality, or to determine the compatibility of a transplant organ with a potential recipient, or to monitor therapeutic measures.
- Device Description: The "Device Description" further clarifies that it is an "in vitro diagnostic assay" for the quantitative determination of urea nitrogen in human samples.
- Performance Studies: The "Summary of Performance Studies" describes comparative performance studies conducted using the assay, which is typical for the validation of an IVD.
The information provided clearly indicates that this device is designed to be used outside of the human body (in vitro) to analyze human specimens (serum, plasma, urine) to provide diagnostic information.
N/A
Intended Use / Indications for Use
The Urea Nitrogen assay is used for the quantitation of urea nitrogen in human serum, plasma, or urine. Measurements obtained by this device are used in diagnosis and treatment of certain renal and metabolic diseases.
Product codes (comma separated list FDA assigned to the subject device)
CDQ
Device Description
Urea Nitrogen is an in vitro diagnostic assay for the quantitative determination of urea nitrogen in human serum, plasma, or urine. The Urea Nitrogen assay is a clinical chemistry assay in which the the urea in the sample is hydrolyzed by urease to ammonia (NH3) and carbon dioxide (CO2). A second reaction, catalyzed by glutamate dehydrogenase (GLD), converts ammonia and a-ketoglutarate to glutamate and water with the concurrent oxidation of reduced nicotinamide adenine dinucleotide (NADH) to nicotinamide adenine dinucleotide (NAD). Two moles of NADH are oxidized for each mole of urea present. The initial rate of decrease in absorbance at 340 nm is proportional to the urea concentration in the sample.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Comparative performance studies were conducted using the ALCYON™ Analyzer. The Urea Nitrogen assay method comparison yielded acceptable correlation with the Roche Cobas Mira Plus Automated Chemistry System Urea Nitrogen assay for the serum application and the Boehringer Mannheim Urea Nitrogen assay on the Hitachi 717 Analyzer for the urine application. For the serum application, the correlation coefficient = 0.9897, slope = 0.963, and Y-intercept = 1.206 mg/dL. For the urine application, the correlation coefficient = 0.9995, slope = 1.046, and Y-intercept = -1.208 mg/dL. Precision studies were conducted using the Urea Nitrogen assay. Within-run, between-run, and between-day studies were performed using two levels of control material. For the serum application, the total %CV for Level 1/Panel 111 is 4.9% and Level 2/Panel 112 is 3.9%. For the urine application, the total %CV for Level 1/Panel 111 control is 3.0% and Level 2/Panel 112 is 3.3%. The Urea Nitrogen assay is linear up to 120 mg/dL. The limit of quantititation (sensitivity) of the Urea Nitrogen assay is 1.8 mg/dL. These data demonstrate that the performance of the Urea Nitrogen assay is substantially equivalent to the performance of the Roche Cobas Mira Plus Automated Chemistry System Urea Nitrogen assay for the serum application and the Boehringer Mannheim Urea Nitrogen assay on the Hitachi 717 Analyzer for the urine application.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
correlation coefficient = 0.9897 (serum); correlation coefficient = 0.9995 (urine); slope = 0.963 (serum); slope = 1.046 (urine); Y-intercept = 1.206 mg/dL (serum); Y-intercept = -1.208 mg/dL (urine); total %CV for Level 1/Panel 111 is 4.9% (serum); total %CV for Level 2/Panel 112 is 3.9% (serum); total %CV for Level 1/Panel 111 control is 3.0% (urine); total %CV for Level 2/Panel 112 is 3.3% (urine); linear up to 120 mg/dL; limit of quantititation (sensitivity) of the Urea Nitrogen assay is 1.8 mg/dL.
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 862.1770 Urea nitrogen test system.
(a)
Identification. A urea nitrogen test system is a device intended to measure urea nitrogen (an end-product of nitrogen metabolism) in whole blood, serum, plasma, and urine. Measurements obtained by this device are used in the diagnosis and treatment of certain renal and metabolic diseases.(b)
Classification. Class II.
0
APR 2 4 1998
510(k) Summary
Submitter's Name/Address Abbott Laboratories 1920 Hurd Drive Irving, Texas 75038
Contact Person Mark Littlefield Section Manager MS 1-8 Regulatory Affairs (972) 518-7861 Fax (972) 753-3367
| Date of Preparation of this Summary: | March 26, 1998 |
|---|---|
| Device Trade or Proprietary Name: | Urea |
| Device Common/Usual Name or Classification Name: | Urea Nitrogen |
| Classification Number/Class: | 75CDQ/Class II |
This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.
The assigned 510(k) number is: K98123 .
Test Description:
Urea Nitrogen is an in vitro diagnostic assay for the quantitative determination of urea nitrogen in human serum, plasma, or urine. The Urea Nitrogen assay is a clinical chemistry assay in which the the urea in the sample is hydrolyzed by urease to ammonia (NH3) and carbon dioxide (CO2). A second reaction, catalyzed by glutamate dehydrogenase (GLD), converts ammonia and a-ketoglutarate to glutamate and water with the concurrent oxidation of reduced nicotinamide adenine dinucleotide (NADH) to nicotinamide adenine dinucleotide (NAD). Two moles of NADH are oxidized for each mole of urea present. The initial rate of decrease in absorbance at 340 nm is proportional to the urea concentration in the sample.
Substantial Equivalence:
The Urea Nitrogen assay is substantially equivalent to the following devices:
Urea Nitrogen 510(k) March 26, 1998 BUNKfinal.lwp
Section II Page 1 0000012
1
- Roche® Cobas Mira® Plus Automated Chemistry System Urea Nitrogen assay • • (K954000) for the serum application
- Boehringer Mannheim® Urea Nitrogen assay on the Hitachi® 717 Analyzer . (K771923) for the urine application
These assays yield similar Performance Characteristics.
Similarities to Roche:
- Both assays are in vitro clinical chemistry methods. .
- Both assays can be used for the quantitative determination of urea nitrogen. .
- Both assays yield similar clinical results. .
Differences to Roche:
-
There is a minor difference between the assay range. .
Similarities to Boehringer Mannheim: -
Both assays are in vitro clinical chemistry methods. .
-
Both assays can be used for the quantitative determination of urea nitrogen. .
-
. Both assays vield similar clinical results.
Differences to Boehringer Mannheim:
- There is a minor difference between the assay range .
Intended Use:
The Urea Nitrogen assay is used for the quantitation of urea nitrogen in human serum, plasma, or urine.
Performance Characteristics:
Comparative performance studies were conducted using the ALCYON™ Analyzer. The Urea Nitrogen assay method comparison yielded acceptable correlation with the Roche Cobas Mira Plus Automated Chemistry System Urea Nitrogen assay for the serum application and the Boehringer Mannheim Urea Nitrogen assay on the Hitachi 717 Analyzer for the urine application. For the serum application, the correlation
Section II Page 2
0000013
2
coefficient = 0.9897, slope = 0.963, and Y-intercept = 1.206 mg/dL. For the urine application, the correlation coefficient = 0.9995, slope = 1.046, and Y-intercept = -1.208 mg/dL. Precision studies were conducted using the Urea Nitrogen assay. Within-run, between-run, and between-day studies were performed using two levels of control material. For the serum application, the total %CV for Level 1/Panel 111 is 4.9% and Level 2/Panel 112 is 3.9%. For the urine application, the total %CV for Level 1/Panel 111 control is 3.0% and Level 2/Panel 112 is 3.3%. The Urea Nitrogen assay is linear up to 120 mg/dL. The limit of quantititation (sensitivity) of the Urea Nitrogen assay is 1.8 mg/dL. These data demonstrate that the performance of the Urea Nitrogen assay is substantially equivalent to the performance of the Roche Cobas Mira Plus Automated Chemistry System Urea Nitrogen assay for the serum application and the Boehringer Mannheim Urea Nitrogen assay on the Hitachi 717 Analyzer for the urine application.
Conclusion:
The Urea Nitrogen assay is substantially equivalent to the Roche Cobas Mira Plus Automated Chemistry System Urea Nitrogen assay for the serum application and the Boehringer Mannheim Urea Nitrogen assay on the Hitachi 717 Analyzer for the urine application as demonstrated by results obtained in the studies.
Urea Nitrogen 510(k) March 26, 1998 BUNKfinal.lwp
Section II Page 3 0000014
3
Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized eagle or bird-like figure with three curved lines representing its body and wings. The bird is positioned to the right of a circular arrangement of text that reads "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA".
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
APR 2 4 1998
Mark Littlefield .Section Manager, Regulatory Affairs Abbott Laboratories 1920 Hurd Drive Irving, Texas 75038
Re: K981123 Urea Nitrogen Requlatory Class: II Product Code: CDQ Dated: March 26, 1998 March 27, 1998 Received:
Dear Mr. Littlefield:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions The general controls provisions of the Act of the Act. include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major requlations affecting your device can be found in the Code of Federal Requlations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set " forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory In addition, FDA may publish further announcements action. concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or requlations.
4
Page 2
Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770) 488-7655.
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html".
Sincerely yours,
Steven Litman
Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
5
510(k) Number (if known): K 981123
Urea Nitrogen Device Name:
Indications For Use:
The Urea Nitrogen assay is used for the quantitation of urea nitrogen in human serum, plasma, or urine. Measurements obtained by this device are used in diagnosis and treatment of certain renal and metabolic diseases.
ﺎﺕ ﺍﻟﻤ (PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED) ... ... . . . . . . . Concurrence of CDRH, Office of Device Evaluation (ODE) Prescription Use Over-The-Counter Use _________________________________________________________________________________________________________________________________________________________ OR (Per 21 CFR 801.109) (Optional Format 1-2-96) (Division Sign-Off) Division of Clinical Laboratory Devices. 510(k) Number .
く
2
00000006